The primary purpose of this study is to determine if giving the combination therapy
consisting of Thymoglobulin® (ATG) and Neulasta® (GCSF) to patients with established Type 1
Diabetes (T1D) is safe and secondarily, if the ATG and GCSF will preserve insulin production.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Florida
Collaborators:
Genzyme, a Sanofi Company The Leona M. and Harry B. Helmsley Charitable Trust